Scarica l'app Stockscreener
2.41
10.41%
-0.28
Dopo l'orario di chiusura:
2.41
Precedente Chiudi:
$2.69
Aprire:
$2.68
Volume 24 ore:
45,506
Relative Volume:
3.81
Capitalizzazione di mercato:
$3.50M
Reddito:
-
Utile/perdita netta:
$-8.22M
Rapporto P/E:
-0.3237
EPS:
-7.4459
Flusso di cassa netto:
$-4.78M
1 W Prestazione:
-4.17%
1M Prestazione:
-1.06%
6M Prestazione:
-15.14%
1 anno Prestazione:
-42.21%
Intervallo 1D:
$2.385
$2.68
Intervallo di 1 settimana:
$2.385
$2.7632
Portata 52W:
$1.84
$5.05
Synaptogenix Inc Stock (SNPX) Company Profile
Nome
Synaptogenix Inc
Settore
Industria
Telefono
(973) 242-0005
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Confronta SNPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNPX
Synaptogenix Inc
|
2.41 | 3.50M | 0 | -8.22M | -4.78M | -7.4459 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Synaptogenix Inc Borsa (SNPX) Ultime notizie
Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update - Defense World
Synaptogenix (NASDAQ:SNPX) Trading 1.5% Higher – Here’s What Happened - Defense World
Geode Capital Management LLC Takes $39,000 Position in Synaptogenix, Inc. (NASDAQ:SNPX) - Defense World
Synaptogenix stock plunges to 52-week low of $2.14 By Investing.com - Investing.com Canada
Synaptogenix stock plunges to 52-week low of $2.14 - Investing.com Australia
Synaptogenix Inc. (SNPX) reports earnings - qz.com
Will Synaptogenix Make A Mark In Synaptic Regeneration? - RTTNews
Synaptogenix stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Synaptogenix stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why - Defense World
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com
Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World
Synaptogenix forms committee to explore strategic opportunities - Investing.com
Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa
Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India
Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. - mg Magazine
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com
Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today
Bryostatin found to slow cognitive decline in advanced Alzheimer's... - Alzheimer's News Today
Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the MarketAzafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos Health - PR Newswire
Best Penny Stocks To Buy Now? 10 Under $1 To Watch - Penny Stocks
Phase 1 trial of bryostatin-1 in MS expected by year's end |... - Multiple Sclerosis News Today
Oblong Appoints Two New Directors to its Board - Business Wire
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix reports data from Phase II Alzheimer’s trial - Clinical Trials Arena
Synaptogenix's Alzheimer's prospect flops in NIH-sponsored study, sinking stock - Fierce Biotech
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Roche's drug failure extends long list of Alzheimer's trial setbacks - Reuters.com
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital - Business Wire
Synaptogenix Announces Corporate Update Conference Call - StockTitan
Allarity Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ALLR - Benzinga
Quoin Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:QNRX - Benzinga
28 Stocks Moving In Tuesday's Mid-Day Session - Yahoo Finance
Synaptogenix Inc Azioni (SNPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):